Cambridge Cognition


Cambridge Cognition develops cognition tests, known as CANTAB, that can be used to diagnose early-stage neurological diseases. The rights to the tests were acquired from former Aim company CeNeS Pharmaceuticals. Cambridge Cognition raised 5m at 70p a share prior to floating on 18 April 2013 at a valuation of 11.8m.

Sector: Health

News blog

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds